COTA, Inc. Announces Headquarter Relocation to Boston for Continued Growth

01 August, 2019

COTA, Inc., a healthcare technology company that uses real-world evidence to bring clarity to cancer care, has announced that the Company’s headquarters will be relocating to Boston on August 1, 2019. The Company will maintain a New York City presence, but will continue to grow and reinforce its operational activities in Boston. Boston’s robust health technology and life science industries fit perfectly with COTA’s mission of improving cancer care. The Company will be located at 101 Arch Street

 
Related News
COTA to attend ASCO May 31st – June 4th, 2019
05.31.19
Attending #ASCO19 5/31-6/4? Stop by Booth #2063 to learn how COTA organizes fragmented, often hidden data from the real world to provide a clear view of cancer or schedule a demo with us here: meetus@cotahealthcare.comFind more details about the attending here. Read Full Release
COTA Signs Research Collaboration Agreement With The U.S. Food and Drug Administration
05.29.19
COTA, Inc., a leading precision medicine technology company that uses real-world evidence to bring clarity to cancer care, today announced it has signed a two-year Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) Information Exchange and Data Transformation (INFORMED) Program, the Agency's data science and technology incubator supporting regulatory science research. This RCA will establish a study protocol with an initial focus on breast cancer, and will provide the FDA with information on the evolving treatment landscape, including insight on treatment variation within defined subpopulations of patients with the disease. As the project advances, the research may expand to other cancer types and explore disease characteristics, treatment patterns, and patient outcomes for the broader application of precision medicine. Read Full Release
COTA Collaborates with Novartis Pharmaceuticals Corporation
03.27.17
Cota Healthcare, the leading data and technology platform for value-based precision medicine, today announced the signing of a major, multi-year collaboration with Novartis Pharmaceuticals Corporation to help improve clinical and cost outcomes for breast cancer patients. As part of this agreement, which expands significantly on the previous announced collaboration entered into January 2016, teams from across Novartis Pharmaceuticals Corporation will leverage Cota's research-grade, real-world evidence, web-based analysis and visualization tools, and be supported by Cota's medical, data science, and technology experts. Utilizing the real-world evidence and technology platform supplied by Cota is expected to enable Novartis Pharmaceuticals Corporation to accelerate clinical development of new therapies for breast cancer and identify which patients will benefit most. Read Full Release